Cargando…

Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer

BACKGROUND: The aim of this study was to identify the ferroptosis induced tumor microenvironment (FeME) landscape in bladder cancer (BCa) for mRNA vaccine development and selecting suitable patients for precision treatment. METHODS: Gene expression profiles and clinical information of 1216 BCa patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Gui, Cheng-Peng, Li, Jia-Ying, Fu, Liang-Min, Luo, Cheng-Gong, Zhang, Chi, Tang, Yi-Ming, Zhang, Li-zhen, Shu, Guan-nan, Wu, Rong-Pei, Luo, Jun-Hang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261131/
https://www.ncbi.nlm.nih.gov/pubmed/35818395
http://dx.doi.org/10.1186/s40537-022-00641-z
_version_ 1784742205695459328
author Gui, Cheng-Peng
Li, Jia-Ying
Fu, Liang-Min
Luo, Cheng-Gong
Zhang, Chi
Tang, Yi-Ming
Zhang, Li-zhen
Shu, Guan-nan
Wu, Rong-Pei
Luo, Jun-Hang
author_facet Gui, Cheng-Peng
Li, Jia-Ying
Fu, Liang-Min
Luo, Cheng-Gong
Zhang, Chi
Tang, Yi-Ming
Zhang, Li-zhen
Shu, Guan-nan
Wu, Rong-Pei
Luo, Jun-Hang
author_sort Gui, Cheng-Peng
collection PubMed
description BACKGROUND: The aim of this study was to identify the ferroptosis induced tumor microenvironment (FeME) landscape in bladder cancer (BCa) for mRNA vaccine development and selecting suitable patients for precision treatment. METHODS: Gene expression profiles and clinical information of 1216 BCa patients were extracted from TCGA-BLCA, three GEO databases and IMvigor210 cohort. We comprehensively established the FeME landscape of 1216 BCa samples based on 290 ferroptosis related genes (FRGs), and systematically correlated these regulation patterns with TME cell-infiltrating characteristics. Besides, we identified the patients’ ferroptosis risk index (FRI) to predict the prognosis of BCa for precise treatment. RESULTS: Six over-expressed and mutated tumor antigens associated with poor prognosis and infiltration of antigen presenting cells were identified in BCa. Furthermore, we demonstrated the evaluation of FeME within individual tumors could predict stages of tumor inflammation, subtypes, genetic variation, and patient prognosis. Then, 5-lncRNA signature was mined to produce the FRI. Low FRI was also linked to increased mutation load, better prognosis and enhanced response to anti-PD-L1 immunotherapy. Besides, an immunotherapy cohort confirmed patients with lower FRI demonstrated significant therapeutic advantages and clinical benefits. CONCLUSIONS: TFRC, SCD, G6PD, FADS2, SQLE, and SLC3A2 are potent antigens for developing anti-BCa mRNA vaccine. Establishment of FRI will contribute to enhancing our cognition of TME infiltration characterization and guiding more effective immunotherapy strategies and selecting appropriate patients for tumor vaccine therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40537-022-00641-z.
format Online
Article
Text
id pubmed-9261131
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92611312022-07-07 Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer Gui, Cheng-Peng Li, Jia-Ying Fu, Liang-Min Luo, Cheng-Gong Zhang, Chi Tang, Yi-Ming Zhang, Li-zhen Shu, Guan-nan Wu, Rong-Pei Luo, Jun-Hang J Big Data Research BACKGROUND: The aim of this study was to identify the ferroptosis induced tumor microenvironment (FeME) landscape in bladder cancer (BCa) for mRNA vaccine development and selecting suitable patients for precision treatment. METHODS: Gene expression profiles and clinical information of 1216 BCa patients were extracted from TCGA-BLCA, three GEO databases and IMvigor210 cohort. We comprehensively established the FeME landscape of 1216 BCa samples based on 290 ferroptosis related genes (FRGs), and systematically correlated these regulation patterns with TME cell-infiltrating characteristics. Besides, we identified the patients’ ferroptosis risk index (FRI) to predict the prognosis of BCa for precise treatment. RESULTS: Six over-expressed and mutated tumor antigens associated with poor prognosis and infiltration of antigen presenting cells were identified in BCa. Furthermore, we demonstrated the evaluation of FeME within individual tumors could predict stages of tumor inflammation, subtypes, genetic variation, and patient prognosis. Then, 5-lncRNA signature was mined to produce the FRI. Low FRI was also linked to increased mutation load, better prognosis and enhanced response to anti-PD-L1 immunotherapy. Besides, an immunotherapy cohort confirmed patients with lower FRI demonstrated significant therapeutic advantages and clinical benefits. CONCLUSIONS: TFRC, SCD, G6PD, FADS2, SQLE, and SLC3A2 are potent antigens for developing anti-BCa mRNA vaccine. Establishment of FRI will contribute to enhancing our cognition of TME infiltration characterization and guiding more effective immunotherapy strategies and selecting appropriate patients for tumor vaccine therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40537-022-00641-z. Springer International Publishing 2022-07-07 2022 /pmc/articles/PMC9261131/ /pubmed/35818395 http://dx.doi.org/10.1186/s40537-022-00641-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Gui, Cheng-Peng
Li, Jia-Ying
Fu, Liang-Min
Luo, Cheng-Gong
Zhang, Chi
Tang, Yi-Ming
Zhang, Li-zhen
Shu, Guan-nan
Wu, Rong-Pei
Luo, Jun-Hang
Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer
title Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer
title_full Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer
title_fullStr Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer
title_full_unstemmed Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer
title_short Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer
title_sort identification of mrna vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261131/
https://www.ncbi.nlm.nih.gov/pubmed/35818395
http://dx.doi.org/10.1186/s40537-022-00641-z
work_keys_str_mv AT guichengpeng identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer
AT lijiaying identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer
AT fuliangmin identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer
AT luochenggong identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer
AT zhangchi identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer
AT tangyiming identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer
AT zhanglizhen identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer
AT shuguannan identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer
AT wurongpei identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer
AT luojunhang identificationofmrnavaccinesandconservedferroptosisrelatedimmunelandscapeforindividualprecisiontreatmentinbladdercancer